Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. We currently have one Phase 3 program, Varespladib Methyl, and two Phase 2 clinical programs, Blisibimod and Varespladib Sodium.

Varespladib Methyl and Varespladib Sodium inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease.

Blisibimod targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren's Syndrome, Graves' Disease and others.

Late Stage Clinical Pipeline

Varespladib Methyl Oral sPLA2	Acute Coronary Syndrome (Cardiovascular Disease)		more
Blisibimod Anti-BLyS/BAFF	Systemic Lupus Erythematosus (Autoimmune Disease)		more
Varespladib Sodium IV sPLA2	Acute Chest Syndrome (Sickle Cell Disease)		more
A-003 Novel sPLA2	Multiple Indications		more
A-101 Novel sPLA2	Cardiovascular Diseases		more